UMMC Navigation


Main Content

Risk based, response adapted, phase 2 open label trial of nivolumab + brentuximad vedotin for children adolescents and young adults with relapsed/refractory CD30 classic Hodgkin lymphoma

This study is looking at how well certain experimental drugs work in children and adolescents with classical Hodgkin’s lymphoma.

  • Principal Investigator: Dr. Anderson Collier

Who can participate

Those eligible to participate in this study include:

  • Males and females, ages 5-30, with confirmed classical Hodgkin’s lymphoma (cHL), excluding nodular lymphocyte-predominant cHL, after failure of or non-response to first-line therapy.

For more information

  • Maggie Goad
    University of Mississippi Medical Center
    2500 N. State St.
    Jackson MS 39216
    (601) 815-9390 
  • IRB Number: 2017-0165